![](/img/cover-not-exists.png)
Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial
Halota, W., Ferenci, P., Kozielewicz, D., Dybowska, D., Lisovoder, N., Samira, S., Shalit, I., Ellis, R., Ilan, Y.Volume:
22
Language:
english
Journal:
Journal of Viral Hepatitis
DOI:
10.1111/jvh.12369
Date:
August, 2015
File:
PDF, 127 KB
english, 2015